KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD

G. Ferguson (Farmington Hills, United States of America), K. Rabe (Kiel, Germany), F. Martinez (New York, United States of America), L. Fabbri (Gothenberg, Sweden), C. Wang (Beijing, China), M. Ichinose (Sendai, Japan), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), P. Dorinsky (Durham, United States of America)

Source: International Congress 2018 – Clinical trials in COPD: new results
Session: Clinical trials in COPD: new results
Session type: Oral Presentation
Number: 1661
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America), K. Rabe (Kiel, Germany), F. Martinez (New York, United States of America), L. Fabbri (Gothenberg, Sweden), C. Wang (Beijing, China), M. Ichinose (Sendai, Japan), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), P. Dorinsky (Durham, United States of America). KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD. 1661

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: